Sickle Cell Disorders and Severe COVID-19 Outcomes: A Cohort Study
Abstract
Background: Sickle cell disease is a collection of compound heterozygote hemoglobinopathies, including sickle cell anemia (1). The heterozygote hemoglobinopathies are characterized by erythrocyte deformation with hemolysis; immune and coagulation dysfunction; and chronic complications, including pulmonary hypertension and cardiac failure (1, 2). Sickle cell trait is a carrier status for sickle cell disease. Given the established susceptibility to other viral infections and the ethnic “patterning” of sickle cell disorders, affected persons may have increased risks for severe COVID-19. Evidence about COVID19 risks in sickle cell disorders mostly derives from studies of hospitalized persons or selective registries (3–5). Robust LETTERS
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence.
Read the paper
Related studies
- PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0
- Randomized controlled trial for time-restricted eating in healthy volunteers without obesity
- Intracorporeal or Extracorporeal Ileocolic Anastomosis After Laparoscopic Right Colectomy: A Double-blinded Randomized Controlled Trial
- Updates to Male Infertility: AUA/ASRM Guideline (2024)
- Effects of trauma‐informed approaches in schools: A systematic review
- Targeted T cell Therapy in Stage IV Breast Cancer: A Phase I Clinical Trial
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.